SK Chemicals (KRX:285130) aims to reach 2.8 trillion won in revenue, and 320 billion won in operating profit by 2030, according to a filing on Thursday.

The group also targets an 11% operating margin, and return on equity (ROE) above 10% in the same time frame.

The strategy behind those targets includes expanding high-value copoly/monomer offerings, growing functional materials on cost competitiveness, turning recycle profitable, and broadening Pharma's internal medicine reach.

The company also set a shareholder return policy for 2026-2028 targeting a total payout ratio of at least 30%.